Atsumi T, Furukawa S, Amengual O, Koike T
Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Lupus. 2005;14(7):499-504. doi: 10.1191/0961203305lu2145rr.
The pathogenesis of thrombocytopenia in patients with antiphospholipid syndrome (APS) is heterogeneous. Patients with antiphospholipid antibodies (aPL) and thrombocytopenia in the absence of clinical manifestations of APS will be diagnosed and treated as idiopathic thrombocytopenic purpura. However, the presence of aPL places those individuals at particular risk for developing both bleeding and thrombotic complications. Therefore, we propose the inclusion of such patients in the subgroup 'aPL-associated thrombocytopenia'. More attention should be devoted to this subgroup of patients to elucidate the role of aPL in the development of thrombocytopenia and to facilitate the adequate monitoring of its potential thrombotic risk.
抗磷脂综合征（APS）患者血小板减少的发病机制是异质性的。抗磷脂抗体（aPL）阳性且有血小板减少但无APS临床表现的患者将被诊断为特发性血小板减少性紫癜并接受相应治疗。然而，aPL的存在使这些个体有发生出血和血栓并发症的特殊风险。因此，我们建议将此类患者纳入“aPL相关血小板减少症”亚组。应更加关注这一亚组患者，以阐明aPL在血小板减少发生中的作用，并便于对其潜在血栓风险进行充分监测。
